UBE2C and cancer: We showed that patients with higher expression of UBE2C had a shorter overall survival time and worse prognosis, and UBE2C higher-expression levels also resulted in worse DFS prognosis in many cancers, confirming that UBE2C overexpression results in poor clinical outcomes in many tumors.